Evoke Pharma Reports Strong Q2 2025 Sales Growth

Evoke Pharma Inc ( (EVOK) ) has released its Q2 earnings. Here is a breakdown of the information Evoke Pharma Inc presented to its investors.

Evoke Pharma, Inc., a specialty pharmaceutical company, focuses on developing treatments for gastrointestinal disorders, with its flagship product being GIMOTI, a nasal spray for diabetic gastroparesis. In its recent earnings report, Evoke Pharma announced a significant 47% increase in net product sales for the second quarter of 2025, amounting to $3.8 million, compared to the same period last year. This growth is attributed to expanded pharmacy access and increased physician adoption of GIMOTI. The company also saw a 20% rise in new prescribers, indicating growing acceptance among gastroenterology practices.

The financial results for the second quarter of 2025 highlighted a net loss of $1.6 million, slightly higher than the $1.3 million loss in the previous year. Operating expenses rose to $5.3 million, driven by increased profit-sharing with EVERSANA and higher professional fees. Despite the losses, the company maintains a solid cash position with $12.1 million in cash and cash equivalents, which is expected to support operations into the third quarter of 2026.

Evoke Pharma’s strategic focus on GIMOTI continues to show promise, as evidenced by steady refill rates and the presentation of real-world safety data at a major medical conference. The company remains optimistic about its full-year 2025 net product sales guidance of approximately $16 million, reflecting a potential 60% increase over 2024. This outlook considers current trends in prescription growth, expanded pharmacy access, and the ongoing adoption of GIMOTI.

Looking ahead, Evoke Pharma is poised to capitalize on the increasing demand for GIMOTI, while navigating external challenges such as macroeconomic conditions and supply chain constraints. The company’s management remains committed to driving market demand and ensuring the continued success of its flagship product.